Notably, in an exploratory analysis, patients with an aggressive T-follicular helper cell (TFH; inclusive of AITL) PTCL-subset did have a modest PFS benefit with Ro-CHOP as compared to CHOP (19.5 months vs. 10.6 months), although this was not statistically powered to allow a definitive conclusion [41]. The gene discussed is DDIT3; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.